deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL NCT00102752

Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer

A Phase 1/2 Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination With Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma

Sponsor: PPD Development, LP

Conditions Neoplasms Pancreatic Neoplasms
Interventions Gemcitabine Glufosfamide
Updated 8 times since 2017 Last updated: Apr 28, 2009 Started: Dec 31, 2004 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00102752, this PHASE1/PHASE2 trial focuses on Neoplasms and Pancreatic Neoplasms and remains completed. Sponsored by PPD Development, LP, it has been updated 8 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Study Description(click to expand)

This study, TH-CR-301, is a Phase 1/2 study that will evaluate the efficacy and safety of glufosfamide in combination with gemcitabine in advanced solid tumors or in first line treatment of pancreatic cancer. Study Hypothesis: Glufosfamide in combination with gemcitabine may provide benefits in survival to patients with advanced solid tumors or metastatic pancreatic cancer.

This study, TH-CR-301, is a Phase 1/2 study that will evaluate the efficacy and safety of glufosfamide in combination with gemcitabine in advanced solid tumors or in first line treatment of pancreatic cancer.

Study Hypothesis: Glufosfamide in combination with gemcitabine may provide benefits in survival to patients with advanced solid tumors or metastatic pancreatic cancer.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshotCompleted~Oct 2024 – ~Jun 2025 · 8 months · monthly snapshotCompleted~Jun 2025 – present · 10 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jun 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  3. Oct 2024 — Jun 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Completed PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 3 earlier versions

  1. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • PPD Development, LP
  • Threshold Pharmaceuticals
Data source: Threshold Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations